The Association between Cardiovascular Events and the Use of Osteoporosis Medications- Alendronate vs. Raloxifene
碩士 === 國立陽明大學 === 衛生福利研究所 === 97 === Background: With well evidences to lower the risk of fracture, bisphosphonates is the most common medication using to treat osteoporosis. However, in 2007, there was a raising concern about using of bisphosphonates may induce the happening of atrial fibrillatio...
Main Authors: | Pei-Yu Lu, 呂珮瑜 |
---|---|
Other Authors: | Weng-Foung Huang |
Format: | Others |
Language: | zh-TW |
Online Access: | http://ndltd.ncl.edu.tw/handle/3v8p3m |
Similar Items
-
Association between alendronate v.s raloxifene and esophageal diseases among patients with osteoporosis
by: Szu-Chia Tu, et al.
Published: (2012) -
Comparative safety and effectiveness of alendronate versus raloxifene in women with osteoporosis
by: Yeesuk Kim, et al.
Published: (2020-07-01) -
Effects of Alendronate, Calcitonin and Raloxifene Used in the Treatment of Postmenopausal Osteoporosis On Serum No Levels
by: Saliha Karatay, et al.
Published: (2005-03-01) -
The comparison of effects of alendronate and raloxifene treatment in postmenauposal women with osteoporosis - Original Investigation
by: Gülcan Gürer, et al.
Published: (2005-12-01) -
The Comparison of Effects of Alendronate and Raloxifene Treatment in Postmenopausal Women with Osteoporosis - Original Investigation
by: Gülcan Gürer, et al.
Published: (2006-03-01)